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Abstract
The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet
serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by
nitroglycerin. Fifteen female migraineurs (without aura) and eight controls participated in the study. Sublingual nitroglycerin (0.5 mg) was
administered. Blood was collected from the antecubital vein four times: 60 min before and after the nitroglycerin application, and 60 and
120 min after the beginning of the migraine attack (mean 344 and 404 min; 12 subjects). In those subjects who had no migraine attack (11
subjects) a similar time schedule was used. Plasma CGRP concentration increased significantly ðP , 0:01Þ during the migraine attack and
returned to baseline after the cessation of the migraine. In addition, both change and peak, showed significant positive correlations with
migraine headache intensity ðP , 0:001Þ: However, plasma CGRP concentrations failed to change during immediate headache and in the
subjects with no migraine attack. Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects
who experienced a migraine attack. Platelet serotonin content decreased significantly ðP , 0:01Þ after nitroglycerin in subjects with no
migraine attack but no consistent change was observed in patients with migraine attack. In conclusion, the fact that plasma CGRP
concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine. In
contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release
in this model.
q 2003 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Nitroglycerin is an organic nitrate ester that has
vasodilatory properties. The direct formation of nitric
oxide (NO) from organic nitrates has been shown in several
tissues (Tassorelli and Joseph, 1996). Furthermore,
endogenous NO is synthesized by various isoforms of nitric
oxide synthase (NOS) (Ohkuma and Katsura, 2001), which
are encoded by distinct genes (Griffiths et al., 1997). NO is
an important mediator of vasodilatation in intra- and
extracranial blood vessels, and is also an algogenic
substance (Iversen, 1995). This small and almost ubiquitous
messenger molecule does not interact with specific
receptors, but diffuses freely across membranes (Ohkuma
and Katsura, 2001). NO diffuses into vascular smooth
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muscle where it activates soluble guanylate cyclase with the
formation of cyclic guanylate monophosphate (cGMP),
which in turn, relaxes the muscles and dilates the blood
vessels (Zicari et al., 2001). Furthermore, NO modulates the
neuronal release of neurotransmitters in both in vitro and in
vivo conditions (Prast and Philippu, 2001).
Previous studies have shown that migraineurs experience
a delayed migraine-like headache in association with
nitroglycerin administration more often than non-migrai-
neurs (Olesen et al., 1993). It appears that NO initiates a
slow pathological reaction that, eventually, leads to a
headache attack; it is also seen that migraineurs are
supersensitive to both exogenous and endogenous NO
(Olesen et al., 1994). Artificially increased concentrations of
NO are able to increase NO synthase availability in
nociceptive trigeminal neurons (Knyihar-Csillik and
Vecsei, 1999; Pardutz et al., 2000). At the level of the
trigeminal system, neuronal NOS appears to coordinate NO
production to activate calcitonin gene-related peptide
(CGRP) release from trigeminal fibres which in turn triggers
vasodilatation. At the level of the blood vessels themselves,
CGRP appears to activate endothelial NO synthase to cause
further NO production and thus relaxation of blood vessel
smooth muscle with attendant dilation (Akerman et al.,
2002; Goadsby et al., 1990; Lassen et al., 2002; Sarchielli
et al., 2000). However, it is not yet clearly understood why
migraine sufferers respond more severely to NO than the
controls.
The aim of the present study was to evaluate how plasma
CGRP concentration and platelet serotonin content change
in peripheral blood circulation during a reproducible and
accurate human migraine model such as nitroglycerin-
induced headache.
2. Materials and methods
2.1. Study subjects
Fifteen unrelated migraine patients without aura (migrai-
neurs; mean age: 41.9 ^ 2.3 years) and eight unrelated
healthy controls (mean age: 38.5 ^ 4.4 years) were
included in the study. All individuals were females. A
detailed medical history was taken from each subject, and
they underwent complete physical, neurological and
psychological examinations and laboratory studies before
participating in the project. Control subjects have rare (less
than 1/year) and mild headaches only. Patients using
frequent analgesic medications (corresponding to more
than 2 g of aspirin/day) were excluded from the study. The
diagnoses for headache were made according to the criteria
of the International Headache Society (IHS, 1988). None of
the subjects were suffering from psychiatric disorders of any
kind according to the criteria of the DSM-IV (DSM-IV,
1994). At the time of the study, all participants were
medication-free (including oral contraceptives) and were
not following any particular diet. All subjects were studied
during the mid follicular phase (between days 5 and 10 of
the menstrual cycle).
We used an open label case control design. The study
protocol was approved by the local ethics committee for
experimentation on humans and every subject gave written
informed consent before participating in the research.
2.2. Procedure
The subjects arrived at the laboratory at 6.30 a.m. and
were observed until 5.00 p.m. Headache intensity
and characteristics were measured at baseline (7.00 a.m.)
and every 20 min thereafter for the duration of the
observation period. Headache intensity was scored on a
verbal scale that measured from 0 to 10: 1, a very mild
headache including pre-pain (feeling of pressure); 5,
a headache of medium severity; and 10, a very severe
headache. The subjects were asked after the standardized
procedure about pain localization and quality, and side
effects were recorded.
Sublingual administration of 0.5 mg nitroglycerin was
used as a test at 8.00 a.m.
Venous blood was drawn from an antecubital vein four
times during the test day using the Vacutainerw system.
Baseline blood samples were collected at 7.00 a.m. after a
30 min rest period. At 8.00 a.m. subjects received a 0.5 mg
dose of sublingual nitroglycerin. The second blood sample
was taken after sublingual nitroglycerin at 9.00 a.m. The
next two blood samples were taken 60 and 120 min after the
beginning of the migraine attack (mean 344 and 404 min
after nitroglycerin). In subjects with no migraine attack,
similar time schedules were used based on our preliminary
data (third blood sample 5 h and fourth blood sample 6 h
after nitroglycerin).
Subjects were free to withdraw at any time during the
study and treatment was offered if needed. None of the
subjects whose data are presented here received any drug
treatment before the last blood sampling.
2.3. Determination of plasma CGRP level
2.3.1. Drugs and chemicals
Rat Tyr-a-CGRP (23 – 37) (Bachem, Budendorf,
Switzerland), EDTA, Na2HPO4, NaH2PO4 (Reanal, Buda-
pest, Hungary), Aprotinin (Richter, Budapest, Hungary),
30% bovine albumin solution (Sigma, St. Louis, USA) were
used. 125I-labelled Tyr-a-CGRP (23–37) was prepared in
our laboratory (Nemeth et al., 2002). CGRP antiserum was
provided by Dr T. Gorcs, Semmelweis Medical University,
Budapest.
For the determination of plasma CGRP immunoreacti-
vity, venous blood samples (3 ml/patient) were taken into
ice-cold tubes containing EDTA (7.5% 0.072 ml/3 ml
blood) and aprotinin (2700 KIU/3 ml blood). Following
centrifugation (3000 rpm for 15 min at 4 8C) the plasma was
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aspirated and stored at 280 8C until plasma CGRP deter-
mination. Plasma CGRP concentrations were measured by
means of a specific and sensitive radioimmunoassay (RIA)
method (Nemeth et al., 1998). Plasma CGRP concentrations
were measured by examiners who were not familiar with the
subjects participating in the study.
2.4. Determination of platelet serotonin content
The 5-hydroxytriptamine (5-HT) concentration was
determined from platelet-rich-plasma by high-pressure
liquid chromatography (HPLC) coupled with electrochemi-
cal detection as described earlier (Guicheney, 1988; Kantor
et al., 2001). Blood from the cubital vein was obtained in
tubes containing EDTA. Platelet-rich plasma was routinely
prepared by centrifugation and platelets were counted by
phase contrast microscopy. Platelet lyses was induced by
the addition of perchloric acid and methanol. The super-
natant was kept at 280 8C until the assay was performed.
The 5-HT concentration was measured by HPLC that
included an LKB-Pharmacia 2248-010 pump, a 5 C-18
Nucleosil RP column and an electrochemical detector.
Results were calculated from standard and sample peak
height ratios. Serotonin content was expressed in ng/108
platelets. Platelet 5-HT concentrations were measured by
examiners who were not familiar with the subjects
participating in the study.
2.5. Statistical analysis
One-way, two-way and repeated measure analyses of
variance (ANOVA) with post-hoc comparisons (Newman-
Keuls) were applied for testing the statistical differences
between the means of CGRP and 5-HT with regard to
diagnoses and time. Friedman’s non-parametric ANOVA
was used to test changes in headache scores over time.
Statistical differences in headache scores among groups were
compared using the Mann–Whitney U test. Significance
levels were adjusted for multiple comparisons using a
Bonferroni correction. The x2 test was applied for statistical
analysis to search for any differences between the ratios of
patients who experienced headache in the different groups.
Correlation for headache scores versus 5-HT or CGRP
concentration was quantified using the Spearman rank
correlation coefficient. Correlation for basal CGRP concen-
trations versus peak CGRP changes was done with Pearson
product moment correlation test. All procedures were carried
out using Statistica 5 for Windows (StatSoft, 1997). Results
were presented as the mean ^ standard error of mean;
P , 0:05 was considered significantly different.
3. Results
All data were analyzed in two separate ways, primarily
according to the development of migraine attack (migraine
attack versus no migraine attack, see Figs. 1–4), and
secondly according to the clinical diagnosis (migraineurs
versus controls, see Tables 1–3).
3.1. Headaches
Two out of the eight control subjects and 10 out of the 15
migraineurs developed an immediate headache (mean
Fig. 1. Effects of nitroglycerin (0.5 mg sublingual) on headache scores (0–
10 verbal scale) in subjects with migraine attack ðn ¼ 12Þ and subjects with
no migraine attack ðn ¼ 11Þ: Values are mean ^ SEM headache scores.
Baseline blood samples were collected at 7.00 a.m. A secondary blood
sample was taken 1 h after sublingual application of nitroglycerin, at 9.00
a.m. The next two blood samples were taken 60 (migraine 1) and 120 min
(migraine 2) after the beginning of the migraine attack (mean 344 and
404 min after nitroglycerin). In subjects with no migraine attack, similar
time schedules were used based on our preliminary data (migraine 1: 5 h
and migraine 2: 6 h after nitroglycerin, respectively). *Significant changes
after sublingual nitroglycerin compared to baseline, P , 0:01:
Fig. 2. Effects of nitroglycerin (0.5 mg sublingual) on plasma CGRP
concentrations in subjects with migraine attack ðn ¼ 12Þ and subjects with
no migraine attack ðn ¼ 11Þ: Values are mean ^ SEM CGRP concen-
trations. Baseline blood samples were collected at 7.00 a.m. A secondary
blood sample was taken 1 h after sublingual application of nitroglycerin, at
9.00 a.m. The next two blood samples were taken 60 (migraine 1) and
120 min (migraine 2) after the beginning of the migraine attack (mean 344
and 404 min after nitroglycerin). In subjects with no migraine attack,
similar time schedules were used based on our preliminary data (migraine
1: 5 h and migraine 2: 6 h after nitroglycerin, respectively). ^Significant
difference in baseline values, P , 0:05: Significant changes after
sublingual nitroglycerin compared to baseline, *P , 0:05; **P , 0:001:
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latency: 12.5 ^ 4.7 min) after the nitroglycerin test (sub-
lingual 0.5 mg), see Tables 1 and 2. This headache did not
fulfill the IHS criteria for migraine without aura (median
headache score 1, range 0–4), lasting only a few minutes
(mean 31.7 ^ 5.2 min), and disappearing spontaneously.
Typical migraine attacks that fulfilled the IHS criteria for
migraine without aura, developed in two of the control
subjects and 10 of the migraineurs (median headache score
3.5, range 2–7). Characteristics and accompanying symp-
toms of usual migraine headache and migraine-type
headache after nitroglycerin are summarized in Table 2.
Out of the 12 subjects with migraine attack, only seven had
immediate headache, see Tables 1 and 2. The mean latency
for the migraine attacks was 284.2 ^ 90.3 min.
Immediate headache and migraine headache scores in
subjects with no migraine attack and in subjects with
migraine attack are shown in Fig. 1. There was no
significant difference in immediate headache scores
between the two groups (Mann – Whitney U test:
U ¼ 61:0; P ¼ 0:76).
There was a statistically significant increase in headache
scores (Friedman ANOVA: x2 ¼ 20:7; N ¼ 15; df ¼ 3;
P , 0:00012) only in migraineurs, see Table 3. As
expected, migraine headache developed more frequently
among migraineurs (x2 test: x2 ¼ 3:63; df ¼ 1; P ¼ 0:057)
and the severity of the attacks was also higher. For further
information about the headache characteristics of migraine
attacks and accompanying symptoms, see Table 2.
3.2. Basal neurochemical measures
3.2.1. According to the development of headache
Basal CGRP concentrations were significantly higher
(one-way ANOVA: F ¼ 6:65; df ¼ 1; 21; P ¼ 0:018) in
those subjects who developed migraine attack
(20.2 ^ 1.9 pmol/l) when compared to the subjects with
no migraine attack (14.0 ^ 1.3 pmol/l). In contrast, basal
CGRP concentration was not significantly different in
subjects who developed immediate headache
Fig. 3. Significant correlations were observed between headache scores and
plasma CGRP concentrations at the time of the fourth blood sampling
(Spearman R ¼ 0:78; P , 0:0001; A). Significant correlation was also
observed between headache scores and changes in plasma CGRP
concentration, when compared to the baseline, at the time of fourth blood
sampling (Spearman R ¼ 0:57; P ¼ 0:005; B).
Fig. 4. Effects of nitroglycerin (0.5 mg sublingual) on platelet serotonin
concentrations in subjects with migraine attack ðn ¼ 12Þ and subjects with
no migraine attack ðn ¼ 11Þ: Values are mean ^ SEM serotonin concen-
trations. Baseline blood samples were collected at 7.00 a.m. A secondary
blood sample was taken 1 h after sublingual application of nitroglycerin at
9.00 a.m. The next two blood samples were taken 60 (migraine 1) and
120 min (migraine 2) after the beginning of the migraine attack (mean 344
and 404 min after nitroglycerin). In subjects with no migraine attack,
similar time schedules were used based on our preliminary data (migraine
1: 5 h and migraine 2: 6 h after nitroglycerin, respectively). Significant
changes after sublingual nitroglycerin compared to baseline, *P , 0:05;
**P , 0:01:
Table 1
Immediate headache and migraine attack frequency in the study population
Diagnosis
(number)
Immediate
headache
Migraine
attack
Both types
of headache
Yes No Yes No
Migraineurs (15) 10 5 10 5 6
Controls (8) 2 6 2 6 1
Totals 12 11 12 11 7
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(18.8 ^ 1.9 pmol/l) when compared to those without
immediate headache (15.6 ^ 1.8 pmol/l), see Fig. 2.
Basal platelet serotonin content was somewhat lower
(one-way ANOVA: F ¼ 2:74; df ¼ 1; 21; P ¼ 0:11) in
subjects with typical migraine attack (72.8 ^ 8.2 ng/108
pts) when compared to the subjects with no migraine attack
(104.3 ^ 17.8 ng/108 pts). Basal platelet serotonin content
was not significantly different (one-way ANOVA:
Table 2
(a) Clinical characteristics of participants’ usual headache (control subjects have rare—less than 1/year—and mild headaches only). (b) Presence of immediate,
non-migraine type headache within the first hour and clinical characteristics of maximal headache scores from 1 to 12 h after the nitroglycerin test
Subject Immediate
headache
Headache characteristic of usual and NO-induced late headache Accompanying symptoms
Time Localization Intensity Quality Aggravate Nausea Photo Phono IHS
1 a Left Mod/sev Puls Yes Yes Yes Yes M
b No 5 Left 3 Puls Yes No Yes No Yes
2 a Right/left Severe Puls Yes Yes Yes Yes M
b Yes 1 Bilat 4 Cons No No No No No
3 a Left Mod/sev Puls Yes Yes No Yes M
b Yes 6 Bilat 5 Puls Yes Yes No Yes Yes
4 a Left Severe Puls Yes Yes Yes Yes M
b No 7 Bilat 7 Puls Yes Yes Yes Yes Yes
5 a Bilat Mod/sev Puls Yes No Yes Yes M
b Yes 6 Right/bilat 6 Puls Yes No Yes No Yes
6 a Right Severe Puls Yes Yes Yes No M
b Yes 7 Right 6 Puls Yes Yes Yes Yes Yes
7 a Right Mod Puls Yes No Yes No M
b No 0 No No No No No
8 a Left Mod/sev Puls Yes Yes Yes No M
b No 6 Left 4 Puls Yes Yes Yes No Yes
9 a Bilat Mild Cons No No No No CO
b No 0 No No No No No
10 a Right/left Severe Puls Yes Yes Yes Yes M
b Yes 5 Left 3 Puls Yes Yes Yes Yes Yes
11* a Bilat Mild Cons No No No No CO
b Yes 5 Left 2 Puls Yes No Yes Yes Yes
12 a Right Severe Puls Yes Yes Yes Yes M
b Yes 5 Right 3 Puls Yes Yes Yes Yes Yes
13 a Bilat Mild Cons No No No No CO
b Yes 1 Bilat 2 Cons No No No No No
14 a Bilat Mild Cons No No No No CO
b No 0 No No No No No
15 a Bilat Mild Cons No No No No CO
b No 0 No No No No No
16 a Right Severe Puls Yes Yes Yes Yes M
b No 7 Right 2 Puls Yes No Yes Yes Yes
17 a Right Mod/sev Puls Yes Yes Yes No M
b Yes 1 Bilat 3 Cons No No No No No
18 a Bilat Mild Cons No No No No CO
b No 0 No No No No No
19 a Right Mod/sev Puls Yes Yes Yes No M
b Yes 8 Bilat 5 Puls Yes Yes Yes No Yes
20 a Bilat Mod/sev Puls Yes Yes Yes Yes M
b Yes 1 Bilat 1 Cons No No No No No
21** a Bilat Mild Cons No No No No CO
b No 5 Bilat 2 Puls Yes Yes Yes No Yes
22 a Left Severe Puls Yes Yes No No M
b Yes 0 No Yes No No No
23 a Bilat Mild Cons No No No No CO
b No 0 No No No No No
Immediate headache, atypical headache (not fulfilling the IHS criteria for migraine without aura) within the first hour; time, time to peak headache after the
sublingual application of nitroglycerin; localization, bilateral or right/left hemisphere; intensity, intensity of headache scored on a scale from 0 to 10; quality,
constant or pulsating; aggravate, intensity of headache aggravated by physical activity; photo, photophobia; phono, phonophobia; IHS, yes, M, fulfilling the
IHS criteria for migraine without aura; IHS, no, CO, not fulfilling the IHS criteria for migraine without aura. *One bilateral, pulsating headache with vomiting
several years ago. **Rare headaches after sleep deprivation with intensity of headache aggravated by physical activity.
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F ¼ 1:49; df ¼ 1; 21; P ¼ 0:24) in patients with immediate
headache (74.2 ^ 9.3 ng/108 pts) when compared to those
without immediate headache (102.7 ^ 17.4 ng/108 pts), see
Fig. 4.
3.2.2. According to the clinical diagnosis
Basal CGRP concentrations were not significantly higher
in migraineurs when compared to controls (M,
18.4 ^ 1.7 pmol/l; CO, 15.1 ^ 2.0 pmol/l; one-way
ANOVA: F ¼ 1:44; df ¼ 1; 21; P ¼ 0:24), see Table 3.
Basal platelet serotonin content was somewhat lower
(one-way ANOVA: F ¼ 3:24; df ¼ 1; 21; P ¼ 0:086) in
migraineurs (75.5 ^ 7.7 ng/108 pts) when compared to the
control subjects (111.1 ^ 23.3 ng/108 pts), see Table 3.
3.3. Changes in neurochemical measures over time
3.3.1. According to the development of headache
Nitroglycerin highly significantly increased the plasma
CGRP concentration over time during the migraine attack
(two-way ANOVA, no migraine attack vs. migraine attack
subjects: F ¼ 10:17; df ¼ 1; 21; P ¼ 0:004; group £ time
interaction: F ¼ 3:58; df ¼ 3; 63; P ¼ 0:019; Fig. 2). When
separate ANOVA tests were run, significant increase (one-
way ANOVA: F ¼ 6:92; df ¼ 3; 33; P ¼ 0:001) in plasma
CGRP concentrations were found in subjects with migraine
attack but not in the subjects with no migraine attack (one-
way ANOVA: F ¼ 0:57; df ¼ 3; 30; P ¼ 0:63), see Fig. 2.
Our results demonstrate that there is strong correlation
between plasma CGRP concentrations and migraine
headache scores (Spearman R ¼ 0:70; P , 0:001 and
Spearman R ¼ 0:78; P , 0:0001 in the 60th and
120th min after the beginning of migraine, respectively;
Fig. 3). In addition, the changes in plasma CGRP content
when compared to the basal values, showed significant
correlation with migraine headache intensity (Spearman
R ¼ 0:55; P ¼ 0:006 and Spearman R ¼ 0:57; P ¼ 0:005 in
the 60th and 120th min after the beginning of migraine,
respectively; Fig. 3). Furthermore, the peak changes of
plasma CGRP concentrations when compared to basal
values, showed significant correlation with basal CGRP
concentration (Pearson R ¼ 0:45; P ¼ 0:034).
There were, however, no significant changes (one-way
ANOVA: F ¼ 1:79; df ¼ 1; 11; P ¼ 0:21) in plasma CGRP
concentrations during the immediate headache, and the
immediate headache scores did not correlate with the
plasma CGRP concentration (Spearman R ¼ 0:1;
P ¼ 0:63).
An early and long-lasting decrease in platelet serotonin
content (one-way ANOVA: F ¼ 4:85; df ¼ 3; 30;
P ¼ 0:007) was found during the nitroglycerin test in
those subjects who did not develop a migraine attack but not
in the subjects who experienced a migraine attack (one-way
ANOVA: F ¼ 0:17; df ¼ 3; 33; P ¼ 0:92; Fig. 4). The
decrease in platelet serotonin content was prolonged, and
had not yet returned to the starting level at the time of the
last blood sampling.
Furthermore, in subjects without immediate headache, a
significant decrease in platelet serotonin content was
observed 60 min after the nitroglycerin test (one-way
ANOVA: F ¼ 5:2; df ¼ 1; 10; P ¼ 0:046). There were no
significant changes in platelet serotonin content in those
subjects who developed an immediate headache (one-way
ANOVA: F ¼ 0:05; df ¼ 1; 11; P ¼ 0:83). A significant
negative correlation was observed between immediate
headache scores and platelet serotonin content 60 min
after nitroglycerin, when data of all subjects were included
in the analysis (Spearman R ¼ 20:45; P ¼ 0:03).
3.3.2. According to the clinical diagnosis
Generally, nitroglycerin showed a strong tendency to
increase the plasma CGRP concentration over time (two-
way ANOVA: F ¼ 2:56; df ¼ 3; 63; P ¼ 0:06) but there
was no significant difference between migraineurs and the
control subjects (two-way ANOVA, migraineurs vs. control
subjects: F ¼ 1:77; df ¼ 1; 21; P ¼ 0:2; group £ time
interaction: F ¼ 1:63; df ¼ 3; 63; P ¼ 0:19). When separate
ANOVA tests were run, a significant increase in plasma
CGRP concentrations was found in migraineurs (one-way
ANOVA: F ¼ 4:24; df ¼ 3; 42; P ¼ 0:01) but not in the
control subjects (one-way ANOVA: F ¼ 0:96; df ¼ 3; 21;
P ¼ 0:43), see Table 3.
Generally, nitroglycerin showed a tendency to decrease
platelet serotonin concentration over time (two-way
Table 3
Headache scores, plasma CGRP concentrations and platelet serotonin concentrations (mean ^ SEM) in controls and migraineurs during the nitroglycerin test
Time Controls (mean ^ SEM) Migraineurs (mean ^ SEM)
B 1 2 3 B 1 2 3
Headache scores (1–10) 0.0 ^ 0.0 0.25 ^ 0.25 0.5 ^ 0.33 0.5 ^ 0.33 0.2 ^ 0.10 1.0 ^ 0.35 2.4 ^ 0.48** 2.6 ^ 0.53**
Plasma CGRP (pmol/l) 15.1 ^ 2.0 17.5 ^ 2.3 16.5 ^ 2.3 15.3 ^ 2.0 18.4 ^ 1.7 19.7 ^ 1.9 22.2 ^ 2.6** 21.0 ^ 2.4*
Platelet serotonin (ng/108 plts) 111.1 ^ 23.3 97.7 ^ 20.0* 101.0 ^ 21.3* 98.1 ^ 18.9* 75.5 ^ 7.7 73.6 ^ 5.8 70.2 ^ 5.9 73.2 ^ 5.9
Baseline blood samples were collected at 7.00 a.m. A secondary blood sample was taken 1 h after the sublingual application of nitroglycerin, at 9.00 a.m.
The next two blood samples (2 and 3) were taken 60 and 120 min, respectively, after the beginning of a migraine attack (mean 344 and 404 min after
nitroglycerin). In subjects with no migraine attack, similar time schedules were used based on our preliminary data (2: 5 h and 3: 6 h after nitroglycerin,
respectively). Significant changes after sublingual nitroglycerin compared to baseline, *P , 0:05; **P , 0:01:
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ANOVA: F ¼ 2:07; df ¼ 3; 63; P ¼ 0:099) and there was a
slight difference between migraineurs and control subjects
(two-way ANOVA, migraineurs vs. control subjects:
F ¼ 2:97; df ¼ 1; 21; P ¼ 0:11; group £ time interaction:
F ¼ 1:03; df ¼ 3; 63; P ¼ 0:39). When separate ANOVA
tests were run, a significant decrease in platelet serotonin
concentration was found in the control subjects (one-way
ANOVA: F ¼ 4:22; df ¼ 3; 21; P ¼ 0:017) but not in
migraineurs (one-way ANOVA: F ¼ 0:39; df ¼ 3; 42;
P ¼ 0:76), see Table 3.
3.3.3. Return of elevated CGRP concentration after
the cessation of migraine attack
Further blood samples were available from two patients
after the migraine attack was eased using sumatriptan. In
these patients, plasma CGRP concentration had decreased to
the basal value (Headache: basal, 0 and 0; maximal, 3 and 3;
after treatment, 0 and 1. CGRP: basal, 20.7 and 22.4 pmol/l;
at the time of maximal headache, 26.3 and 26.5 pmol/l; after
treatment, 19.8 and 20.2 pmol/l) but no consistent changes
were observed in platelet serotonin concentration (Platelet
5-HT: basal, 52.8 and 68.6 ng/108 pts; at the time of
maximal headache, 70.4 and 66.9 ng/108 pts; after treat-
ment, 72.2 and 49.3 ng/108 pts).
4. Discussion
The aim of the present study was to evaluate the
neurochemical changes after sublingual nitroglycerin appli-
cation that may cause headache in migraineurs and sensitive
healthy subjects. Even low doses of sublingual nitroglycerin
are able to evoke a migraine attack in sensitive patients.
High doses even cause a migraine-type headache in non-
migraineurs (Castellano et al., 1998; Christiansen et al.,
2000; Iversen and Olesen, 1996). In our study, 10 out of the
15 migraineurs and two out of the eight controls developed a
typical migraine attack during the nitroglycerin test.
Previously all control subjects had only rare (less than
1/year) and mild headaches. However, one out of the two
controls who experienced migraine attack, had one bilateral,
pulsating headache with vomiting several years ago and the
other had rare headaches after sleep deprivation with the
intensity of the headache aggravated by physical activity.
These signs may predict sensitivity to NO and the
development of the provoked headache in these subjects.
The relatively variable effectiveness of sublingual nitro-
glycerin on headache, allowed us to compare induced
headache to that of the neurochemical responses in those
subjects who developed typical migraine attack and those
did not. Furthermore, correlation between the intensity of
the migraine attack and the neurochemical measures could
be evaluated.
Trigeminal activation may lead to the release of CGRP
into the cranial circulation, both in humans and in animal
models (Goadsby et al., 1990; Knyihar-Csillik et al., 1997;
Lassen et al., 2002). Several primary headaches, such as
migraine (Goadsby et al., 1990; Sarchielli et al., 2000),
cluster (Fanciulacci et al., 1995; Edvinsson, 2000) and
chronic paroxysmal hemicrania (Goadsby and Edvinsson,
1996) are associated with an increase in the CGRP level in
the external and/or internal jugular vein during a pain attack.
In addition, trigeminovascular activation has been shown to
increase CGRP concentration in the jugular vein too.
Similar, but less pronounced changes, were also seen in
young migraineurs when CGRP was measured in the
antecubital vein during the spontaneous migraine attacks
(Gallai et al., 1995). Another study suggested that
NO-induced immediate headache was not associated with
the release of CGRP (Ashina et al., 2001).
Our results showed consistent, highly significant
increases, in the peripheral plasma CGRP concentration
during the nitroglycerin-induced migraine attack. These
data support the hypothesis that migraine attacks are a result
of trigeminovascular activation (Akerman et al., 2002). It
seems that nitroglycerin triggers a cascade of events that
subsequently lead to the release of CGRP in subjects who
develop migraine attack. The mechanism of NO-induced
pain is not clear, but animal studies suggest, that CGRP
release does not require the production of cGMP, because
guanilate cyclase inhibitor does not prevent NO-induced
CGRP release (Garry et al., 2000).
In our study, plasma CGRP concentration failed to
increase during the immediate headache. These data support
the conclusion of previous studies (Ashina et al., 2001;
Eltrop et al., 2000). This suggests that the initial headache
may be caused by a direct action of the NO-cGMP pathway,
that causes vasodilatation by vascular smooth muscle
relaxation, independently of the CGRP release (Akerman
et al., 2002).
It has been suggested that plasma levels of CGRP in the
peripheral circulation are increased in adult migraineurs
interictally (Ashina et al., 2000). It is remarkable that our
results demonstrate that the higher basal plasma CGRP
concentrations predispose subjects to develop migraine
attack during the nitroglycerin test. In our study, increase in
the CGRP concentrations correlates markedly with the
migraine headache intensity. Furthermore, CGRP concen-
tration returned to baseline after the migraine headache had
ceased. These data suggest that blocking CGRP synthesis,
release or receptors, may successfully prevent or alleviate
migraine pain (Akerman et al., 2002; Buzzi and Moskowitz,
1992; Doods et al., 2000; Durham and Russo, 1999;
Edvinsson, 2001; Goadsby and Edvinsson, 1993; Lassen
et al., 2002). Several drugs, that in various ways antagonize
the effects of CGRP, are presently known to be in pre-
clinical and clinical trials, but no results are available in the
public domain (Doods, 2001).
Thus, it is likely that nitroglycerin-induced migraine
attack can only occur when particular pathophysiological
conditions are present (Lassen et al., 2002). Evidence from
experimental models of pain suggests that NO plays
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a crucial role in both central and peripheral sensitization
(Knyihar-Csillik and Vecsei, 1999; Pardutz et al., 2000,
2002; Reuter et al., 2001). The long latency period, between
nitroglycerin exposure and the fully developed migraine
attack, indicates that the activation of NO—or steps in the
NO-cGMP cascade—initiates a rather slow ongoing process
which results in a migraine attack in sensitive patients. It is
possible that this process takes place in the trigemino-
vascular system, with the increased activity of neuronal
NOS and the consequent activation of trigeminal fibres and
nucleus (Akerman et al., 2002) or in the nociceptive
modulation system (Tassorelli et al., 2002). Furthermore,
increased NOS activity was demonstrated in patients with
chronic daily headache and a previous history of migraine
(Sarchielli et al., 2002), and in migraineurs (D’Amico et al.,
2002; Sarchielli et al., 2000). This higher NOS activity may
cause the higher basal CGRP level and, in addition, the
correlation between the peak changes of plasma CGRP
concentration compared to basal value supports this
hypothesis.
Several investigations support that platelet serotonin
content and its turnover is reduced in migraineurs between
attacks, while the platelet serotonin is released during
migraine crises (Anthony, 1986; Ferrari et al., 1989;
Goadsby, 1997; Juhasz et al., 2003; Nakano et al., 1993;
Sarchielli and Gallai, 2001; Waldenlind et al., 1985). Our
recent data support that the platelet 5-HT concentrations are
somewhat lower in subjects who developed migraine. The
hyposerotonergic status facilitated the pial microvascular
dilation in response to intravenous nitroglycerin infusion in
an animal model (Srikiatkhachorn et al., 2001). Further-
more, increased NOS activity was observed in a model of
serotonin depletion (Tagliaferro et al., 2001). These results
suggest that a chronic hyposerotonergic condition is one of
the main risk factors that may cause a more intense response
to NO in migraineurs when compared to the responses of the
controls.
According to our knowledge, only one study has
previously investigated the platelet serotonin content during
a nitroglycerin-induced headache attack and it failed to
show any changes (Dalsgaard-Nielsen et al., 1975). In our
studies, we could not detect any significant changes in
platelet serotonin content in the subjects with nitroglycerin-
induced migraine attack. On the other hand, an early and
prolonged, highly significant decrease in platelet serotonin
content was found in those subjects who did not develop
migraine attack during the nitroglycerin test. These data
provide evidence for a massive release of serotonin in
subjects who did not develop migraine attack. This
serotonin release, by acting on 5-HT1B/1D receptors such
as tryptans, may cause vasoconstriction and inhibition of
evoked trigeminal nucleus firing, release of CGRP and other
inflammatory peptides from perivascular nerve terminals,
and thus alleviates inflammation and pain (Goadsby and
Hoskin, 1998; Johnson et al., 1998; Knyihar-Csillik et al.,
1997, 2001). In this regard, changes in 5-HT content do not
causally relate to migraine, but secondarily, 5-HT may
influence the neurochemical changes during the migraine-
induced pain attack.
In conclusion, our results support that lower platelet
serotonin concentration and higher basal CGRP concen-
trations are risk factors that express greater susceptibility to
develop both spontaneous and NO-induced migraine attack.
Furthermore, plasma CGRP concentration is a dynamically
changing trait marker for the migraine-induced pain that
suggests a possible causative role of CGRP in migraine. On
the other hand, hyposerotonergic conditions may prevent
the early induced release of serotonin, which may counter-
act pain mechanisms by 5-HT1B/1D receptor activation.
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